Zacks: Analysts Anticipate Recro Pharma Inc (REPH) to Announce -$0.74 Earnings Per Share

Equities research analysts expect Recro Pharma Inc (NASDAQ:REPH) to report ($0.74) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Recro Pharma’s earnings. Recro Pharma reported earnings per share of ($0.81) during the same quarter last year, which suggests a positive year over year growth rate of 8.6%. The company is expected to announce its next quarterly earnings results on Monday, March 5th.

On average, analysts expect that Recro Pharma will report full year earnings of ($2.10) per share for the current financial year. For the next financial year, analysts forecast that the business will report earnings of ($3.13) per share, with EPS estimates ranging from ($4.31) to ($2.12). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Recro Pharma.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative return on equity of 60.01% and a negative net margin of 51.88%.

REPH has been the topic of several recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research note on Friday, October 27th. Zacks Investment Research downgraded Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.65.

Shares of Recro Pharma (REPH) traded up $0.04 during trading on Tuesday, reaching $8.93. The company’s stock had a trading volume of 163,894 shares, compared to its average volume of 87,771. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. The company has a market cap of $170.80, a P/E ratio of -4.08 and a beta of -0.50. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.59.

In other news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the sale, the insider now owns 734,269 shares of the company’s stock, valued at approximately $6,520,308.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $9.58, for a total value of $2,132,661.28. The disclosure for this sale can be found here. Insiders sold a total of 860,414 shares of company stock worth $8,289,916 in the last three months. Company insiders own 21.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC acquired a new stake in shares of Recro Pharma during the second quarter worth $162,000. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma during the second quarter worth $169,000. JPMorgan Chase & Co. raised its position in shares of Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 14,098 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in shares of Recro Pharma during the second quarter worth $215,000. Finally, Wells Fargo & Company MN raised its position in shares of Recro Pharma by 42.5% during the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock worth $220,000 after purchasing an additional 7,308 shares during the period. 61.55% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3149180/zacks-analysts-anticipate-recro-pharma-inc-reph-to-announce-0-74-earnings-per-share.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.